Reduced REM sleep: a potential biomarker for epilepsy - a retrospective case-control study.


Journal

Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979

Informations de publication

Date de publication:
May 2022
Historique:
received: 11 02 2022
revised: 15 03 2022
accepted: 30 03 2022
pubmed: 11 4 2022
medline: 11 5 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

Establishing the diagnosis of epilepsy can be challenging if interictal epileptic discharges (IEDs) or seizures are undetectable. Many individuals with epilepsy experience sleep disturbances. A reduced percentage of REM sleep (REM%) has been observed following seizures. We aimed to assess differences of REM% in individuals with epilepsy in comparison with differential diagnoses. We performed a retrospective, monocentric, two-armed case-control study with 128 age-matched individuals who underwent ≥72 hours of continuous video-EEG monitoring at our epilepsy monitoring unit (EMU) for diagnostic evaluation. We assessed REM% on the first and last night of EMU admission. Logistic regressions models were used to evaluate the predictive value of REM%. We included 64 individuals diagnosed with epilepsy and 64 with a differential diagnosis. REM% in the epilepsy group was significantly lower [12.2% (±4.7) vs. 17.2% (±5.2), p<0.001]. We found no significant influence of sex, age, anti-seizure, or other medications. A REM%-based and an IED and seizure-based regression model were not significantly different [area under the curve (AUC) 0.791 (95% confidence interval (CI): 0.713-0.870) vs. 0.853 (95% CI: 0.788-0.919), p=0.23]. A combined model, based on IEDs, seizures, and REM%, was superior to the IED model alone [0.933 (0.891-0.975), p<0.01]. Our study shows significantly reduced REM% in individuals with epilepsy. REM%-based models show a good predictive performance. REM% assessment could improve diagnostic accuracy - especially for challenging cases, e.g., when IEDs or seizures are absent and patient history and semiology appear ambiguous. REM% as a biomarker should be evaluated in prospective, multicentric trials.

Identifiants

pubmed: 35398671
pii: S1059-1311(22)00071-1
doi: 10.1016/j.seizure.2022.03.022
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-33

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Auteurs

Ufuk Sadak (U)

Department of Epileptology and Neurology, RWTH University Hospital Aachen, Germany.

Philipp Honrath (P)

Department of Epileptology and Neurology, RWTH University Hospital Aachen, Germany.

Ummehan Ermis (U)

Department of Epileptology and Neurology, RWTH University Hospital Aachen, Germany.

Jan Heckelmann (J)

Department of Epileptology and Neurology, RWTH University Hospital Aachen, Germany.

Tareq Meyer (T)

Department of Epileptology and Neurology, RWTH University Hospital Aachen, Germany.

Yvonne Weber (Y)

Department of Epileptology and Neurology, RWTH University Hospital Aachen, Germany; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany.

Stefan Wolking (S)

Department of Epileptology and Neurology, RWTH University Hospital Aachen, Germany. Electronic address: swolking@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH